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ABSTRACT
Introduction: Leprosy is a chronic disease that affects skin and peripheral nerves. Disease complications include reactional 
episodes and physical impairment. One World Health Organization (WHO) goal of leprosy programs is to decrease the number 
of grade 2 impairment diagnoses by 2015. This study aims to evaluate clinical factors associated with the occurrence of leprosy 
reactions and physical impairment in leprosy patients. Methods: We conducted a retrospective study of data from medical 
records of patients followed in two important centers for the treatment of leprosy in Aracaju, Sergipe, Brazil, from 2005 to 
2011. We used the chi-square test to analyze associations between the following categorical variables: gender, age, operational 
classiﬁ cation, clinical forms, leprosy reactions, corticosteroid treatment, and physical impairment at the diagnosis and after cure. 
Clinical variables associated with multibacillary leprosy and/or reactional episodes and the presence of any grade of physical 
impairment after cure were evaluated using the logistic regression model. Results: We found that men were more affected by 
multibacillary forms, reactional episodes, and grade 2 physical impairment at diagnosis. Leprosy reactions were detected in a 
total of 40% of patients and all were treated with corticosteroids. However, physical impairment was observed in 29.8% of the 
patients analyzed at the end of the treatment and our multivariate analysis associated a low dose and short period of corticosteroid 
treatment with persistence of physical impairments. Conclusions: Physical impairment should receive an increased attention 
before and after treatment, and adequate treatment should be emphasized.
Keywords: Leprosy. Leprosy reactions. Physical impairment. Corticosteroid treatment.
Leprosy is a chronic disease caused by infection with 
Mycobacterium leprae. The bacillus affects the skin and 
Schwann cells of the peripheral nerves, resulting in cutaneous 
lesions and neuropathy. Loss of sensory, motor, and autonomic 
nerve function in the eyes, hands, and feet can result in secondary 
complications, such as deformity, impairment, psychological 
disturbances, and social exclusion1,2.
Periods of acute immunologic hypersensitivity known as 
reactional episodes can occur before the diagnosis and during 
or after treatment and cause nerve injury if not appropriately 
treated3. There are two primary types of hypersensitivity 
reaction: type 1 reactions, also referred to as reversal reactions 
(RR) (exacerbation of cellular immunity), and type 2 reactions, 
or erythema nodosum leprosum (exacerbation of humoral 
immunity)3. There is a clear recommendation for corticosteroid 
treatment of severe type 1 reactional episodes by the Brazilian 
Ministry of Health: 1 to 2mg/kg of body weight for at least 
12 weeks. For severe type 2 reactions, the Brazilian Ministry 
of Health recommends the same dose of corticosteroid plus 
thalidomide4.
Assessment of physical impairment in leprosy is employed 
as an epidemiological indicator to evaluate leprosy programs, 
determine early or late diagnosis, and monitor patient follow-
up in health care center over the course of treatment5. The 
World Health Organization’s (WHO) global strategy (2011 to 
2015) aims to reduce the rate of new cases of grade 2 physical 
impairment4. Additionally, early detection of new cases of 
leprosy and corticosteroid treatment for severe reactional 
episodes may prevent future cases of irreversible nerve damage6.
The State of Sergipe is located in northeastern Brazil and is 
a priority for the national leprosy control program. In the last 
seven years, 3,039 patients were registered in the Brazilian 
Information Health System of the Sistema de Informação de 
Agravos de Notiﬁ cação (SINAN), and the percentage of grade 2 
impairments at diagnosis increased between 2005 and 2010 
(from 4.8% to 8.7%). These numbers call attention to the need 
to perform studies evaluating epidemi ological and clinical 
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factors associated with physical impairment7. This study aims 
to evaluate clinical factors associated with the occurrence of 
physical impairment in leprosy patients from two centers for 
the treatment of leprosy patients in Sergipe.
We conducted a retrospective study of data from the medical 
records of patients followed in two centers for the treatment of 
leprosy located in the City of Aracaju, State of Sergipe, Brazil, 
from 2005 to 2011. From a total of 545 records of patients 
diagnosed with leprosy, 51 patients were excluded because 
they did not ﬁ nish the speciﬁ c treatment, were transferred 
during the ﬁ rst two months of treatment, or the records did 
not contain the necessary information. A total of 494 patient 
records were analyzed. The analyzed variables were: gender, 
age (≥ 15 years and < 15 years), the classiﬁ cation of physical 
impairment at diagnosis and after treatment (grade 0, 1 and 2) 
based on the WHO and the Brazilian Ministry of Health standard 
examination, operational classiﬁ cation: paucibacillary (PB) 
and multibacillary (MB), clinical forms (indeterminate leprosy, 
tuberculoid leprosy, borderline leprosy, lepromatous leprosy, and 
pure neural leprosy), reactional episodes, and treatment with 
corticosteroids. We deﬁ ned the type 1 reaction as an episode 
characterized by acute inﬂ ammation in skin lesions or nerves8,9 
and the type 2 reaction as the appearance of inﬂ amed cutaneous 
nodules with or without neuritis9.
Nerve involvement in leprosy is considered to occur when 
there are signs of pain or nerve thickening on palpation of 
the nerves, when there is loss of sensitivity according to the 
monoﬁ lament test, or when any motor impairment is observed. 
However, for this analysis, we only considered the objective 
scale of physical impairment as deﬁ ned by the WHO. This 
scale ranksphysical impairment in leprosy as follows: grade 0 
(no anesthesia and no visible impairment to the eyes, hands, 
or feet), grade 1 (anesthesia but no visible deformities to the 
eyes, hands, or feet), and grade 2 (hand ulcers, absorption or 
contractures of the digits, plantar ulcers, callosities, foot drop, 
or claw). This assessment should be conducted at the beginning 
and the end of treatment or at any time during treatment if the 
patient has a complaint.
The severity of the disease is associated with clinical forms 
with high bacilli loads (MB forms)10,11 or the occurrence of 
reactional episodes12.Thus, we investigated the association of 
the demographic and clinical data with these two variables as 
well as with physical impairment.
Statistical analysis
We created a database in Statistical Package for the Social 
Sciences (SPSS) statistical program version 17.0.0. Categorical 
variables are presented as simple or frequency count sand 
percentages and quantitative variables as means and standard 
deviations. To analyze the associations between categorical 
variables we used thechi-square test. To assess the factors 
associated with MB leprosy and reactional episodes, we used a 
logistic regression model in which MB leprosy and/or reactional 
episode was considered the dependent variable, where as gender 
and physical impairment at diagnosis were the independent 
variables. In addition, the logistic regression model was used to 
evaluate the presence of any grade of physical impairment after 
treatment as the dependent variable and male gender, reactional 
episodes, and a corticosteroid dose lower than 20mg for a period 
less than 30 days as independent variables. We adopted α = 0.05 
as the level of signiﬁ cance.
We analyzed the medical records of 494 patients, 268 (54%) 
men and 226 (46%) women)of the two major centers for the 
treatment of leprosy patients in Sergipe from 2005 to 2011. We 
found similar percentages of PB forms (50.8%; 251/494, 95% CI 
[46.8 to 55.1]) and MB forms (49.2%; 243/494, 95% CI [44.9 
to 53.2]). However, men presented a higher frequency of MB 
forms. Of the 268 men, 162 (60.4%) were affected by MB forms 
compared with 81 (35.8%) of the 226 women (p< 0.001). Physical 
impairment was evaluated and recorded in 396 (80.2%) of the 494 
patients at diagnosis (200 men and 196 women). Men presented 
twice as much grade 2 physical impairment at diagnosis [12% 
(24/200)] as women [6.1% (12/196); p = 0.04], and reactional 
episodes were more frequently observed in MB forms [57.2% 
(139/243); p < 0.0001] and in men [45.1% (121/268)] than in 
women [33.6% (76/226); p = 0.009] (Table 1).
Ages were registered for 488 patients and ranged from 3 to 
85 years (mean ± SD, 41 ± 18.2). Eight percent of the patients 
(39/488) were children aged younger than 15 years. Clinical 
forms were registered in 424 patients. The predominant clinical 
form of leprosy was tuberculoid (TT) [40.1% (170/424)], 
followed by borderline (BB) [20.1% (85/424)], indeterminate 
(IL) [18.4% (78/424)], lepromatous (LL) [17.2% (73/424)], and 
pure neural (PN) [4.2% (18/424)].
Reactional episodes were detected in 40% (197/494; 95%CI 
[35.6 to 44.1]) of the patients and were more frequently observed 
in MB forms [57.2% (139/243); p < 0.0001]. The RR, or the 
type 1 reaction, was the most common [75.1% (148/197)] and 
more frequent during treatment for leprosy.
Figure 1 shows the frequency of recorded physical 
impairment examinations in the 494 patients included in this 
study before and after treatment and the frequency of any grade 
of physical impairment found in the examined patients. At 
diagnosis, 80.2% (396/494) of the patients were evaluated for 
physical impairment, and 36% (143/396) exhibited grade 1 [27% 
(107/396)] or grade 2 [9% (36/396)] physical impairments. After 
treatment, the assessment of physical impairment was recorded 
in only 37.4% (185/494) of patients, and 29.8% (55/185) of 
these patients exhibited physical impairments.
Based on the frequency of grade 1 and 2 of physical 
impairment found after treatment (30%) and considering that an 
examination to evaluate the grade of physical impairment was 
not recorded after treatment for a majority of patients [62.5% 
(309/494)], physical impairment might have been detected 
in 93 additional patients had they been examined. 
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TABLE 1 - Clinical characteristics according to gender of leprosy patients attended from 2005 to 2011 in Sergipe, Brazil.
 Male Female
Variable* % (n/total) % (n/total) p
Operational classiﬁ cation   
paucibacillary form 39.6 (106/268) 64.2 (145/226) 
multibacillary form 60.4 (162/268) 35.8 (81/226) < 0.001
Leprosy reactions 45.1 (121/268) 33.6 (76/226) 0.009
Physical impairment at diagnosis   
grade 0 (no impairment) 61.0 (122/200) 66.8 (131/196) 
grade 1 27.0 (54/200) 27.0 (53/196) 
grade 2 12.0 (24/200) 6.1 (12/196) 0.040
*Chi-square test. 
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FIGURE 1 - Number of leprosy patients with recorded neurological 
examinations and any grade of physical impairment detected at diagnosis and 
at the end of treatment attended in the two major leprosy centers in Sergipe, 
Brazil, from 2005 to 2011.
Of the 494 patients included in this study, 40% (197/494, 
95%CI [35.6 to 44.1]) experienced reactional episodes, and 
all 197 received corticosteroid treatment. However, 162/197 
(82.2%) patients received a dose below 20mg of prednisone 
for less than 30 days. After corticosteroid treatment of these 
162 patients, only 54 underwent neurological assessment at 
the beginning and at the end of the treatment. Of these patients, 
the grade of physical impairment of 52% (28/54) remained 
the same or increased. For instance, of these 54 patients, 26 
patients had grade 0 physical impairment before treatment. 
Of these 26 patients, 18 continued to exhibit no signs of nerve 
injury after treatment, however, 7 patients progressed to grade 
1 and 1 patient to grade 2 physical impairment. Of 23 patients 
presenting with grade 1 physical impairment before treatment, 
14 remained at grade 1, one patient progressed to grade 2, and 
only eight patients improved to grade 0 after treatment. Of 5 
patients diagnosed with grade 2 physical impairment before 
treatment, four patients remained with grade 2, whereas one 
patient improved to grade 1 after treatment. 
To assess the factors associated with MB leprosy and/or 
reactional episode, we used a logistic regression model in 
which MB leprosy and/or reactional episode was a dependent 
variable and gender and grade 1 and 2 of physical impairment 
at diagnosis were independent variables. Table 2 shows an 
independent association between MB leprosy and/or reactional 
episode and factors such as male gender (OR 2.42, 95%CI [1.49 
to 3.95]; p<0.001) and grade 2 (OR 6.32, 95%CI [1.98 to 20.15]; 
p=0.002) or grade 1 (OR 2.72, 95%CI [1.50 to 4.92]; p=0.001) 
physical impairment at diagnosis. When the presence of any 
grade of physical impairment after cure was evaluated as a 
dependent variable with male gender, age, reactional episodes, 
and a corticosteroid dose lower than 20mg for a period less than 
30 days as independent variables, we observed an independent 
association of the presence of any grade of physical impairment 
after cure with this treatment regimen (OR 4.94, 95%CI [2.49 
to 9.82]; p<0.001). No associations with male gender, age, and 
leprosy reactions were detected.
The morbidity associated with leprosy is related to 
multiple skin lesions observed in MB forms11, leprosy 
reactions12, and physical impairment13, which are the disease’s 
  603
primary complications. It is important to identify the clinical 
characteristics that can predict these deleterious outcomes. In this 
study, we found independent associations of male gender with 
MB forms, leprosy reactions, and physical impairment. A higher 
prevalence of leprosy in men is reported by others2,13,14 as well 
as associations between male gender and MB forms of leprosy7, 
leprosy reactions15, and physical impairment7. This frequency of 
complication among men might be related to socio-cultural issues, 
such as higher exposure as a result of more intense social or work 
activities, less pursuit of health care, and the fear of losing one’s 
employment because of the stigma of leprosy2.
Interestingly, in leishmaniasis, which is another disease 
caused by an intracellular organism, epidemiological data and 
experimental animal studies also suggest higher susceptibility 
in males16. A study using an experimental model of infection by 
Paracoccidioides braziliensis demonstrated the inﬂ uence of sex 
hormones on the immune response, revealing that testosterone 
promotes an increased production of interleukin-10 (IL-10), and 
less protection against this infection17. There is no study on this 
issue in the context of leprosy.
The global strategy for the control of leprosy from 2011 to 
2015 aims to reduce the rate of new cases with grade 2 physical 
impairment worldwide by more than 35% by the end of 2015, 
compared with the baseline at the end of 20104. The number of 
thickened nerves is signiﬁ cantly associated with increased risk 
for physical impairments2,18. Furthermore, physical impairment 
at diagnosis has been associated with a worse prognosis for 
deformities19,20.
The proportion of patients evaluated using a neurological 
examination and diagnosed with physical impairment facilitates 
an indirect assessment of the effectiveness of programs to 
TABLE 2 - Logistic regression analysis of factors associated with multibacillary/leprosy reaction and physical impairment after treatment  in 
leprosy patients attended from 2005 to 2011 in Sergipe, Brazil.
Dependent variables Independent variables OR 95% CI p
Multibacillary/leprosy reaction
 Gender   
 male 2.42 1.49-3.45 <0.0001
 female 1  
 Physical impairment at diagnosis   
 grade 2 6.32 1.98-20.15 <0.002
 grade 1 2.72 1.50-4.92 <0.001
 grade 0 1  
Physical impairment after treatment*
 Corticosteroid treatment dose    
  < 20mg for < 30 days 4.94 2.49-9.82 <0.001
 higher doses 1  
Model: Logistic regression after adjustment of the model (Forward Stepwise); *Variables that were not associated independently with physical 
impairment after treatment: gender (p=0.44), age (p=0.17), and reactional episode (p=0.24). OR: odds ratio; CI: conﬁ dence interval.
prevent impairment18.The Brazilian Ministry of Health has 
established that the physical impairment evaluation should be 
performed in at least 90% of the leprosy patients at diagnosis 
and 75% after treatment. In the present study, we demonstrate 
that leprosy reactions and physical impairment are frequent in 
this population. However, a number of patients in these medical 
centers are not tested for impairment at diagnosis and a larger 
number of patients are not assessed at the end of treatment. 
These results may reﬂ ect problems with professional training 
for the prevention of leprosy-related physical impairment. It is 
essential to develop strategies that emphasize the importance of 
the neurological examination to prevent physical impairments19.
Leprosy reactions are associated with the development of 
physical impairments. Early identiﬁ cation combined with the 
proper treatment of leprosy reactions can be an effective strategy 
to prevent physical impairment in leprosy13,14. Prednisone is the 
drug of choice not only for the treatment of leprosy reactions and 
silent neuritis events21 but also to reduce swelling and prevent 
further physical impairment18.
The Brazilian Ministry of Health guidelines suggest the 
administration of 1 to 2mg/kg of prednisone daily for at least 90 
days to treat severe reactions19. However, in this study, patients 
were treated with smaller doses of steroids over a shorter period. 
This approach may be insufﬁ cient to reverse nerve damage, 
resulting in a high frequency of physical impairment after 
treatment. In fact, in the present study, we demonstrated an 
independent association between the persistence of physical 
impairment after treatment and treatment with corticosteroids 
in a dose lower than 20mg for a period less than 30 days.
Although there is a clear recommendation by the Brazilian 
Ministry of Health to treat leprosy reactions with corticosteroids, 
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controversy remains regarding the dose and duration of 
corticosteroid treatment that is necessary to prevent physical 
impairment. A multicenter study in Bangladesh and Nepal 
demonstrated a decrease in primary outcome events of leprosy-
related reactions and associated impairment of nerve function by 
prophylactic oral corticosteroids for 4 months in MB patients. 
However, this signiﬁ cant effect was not sustained after one 
year22. A clinical trial using oral corticosteroids for neuropathy 
demonstrated that during the ﬁ rst month higher doses of steroids 
produced better results. However, earlier treatment with lower 
doses was also effective23. The administration of the correct dose 
of prednisone improved the clinical and electrophysiological 
condition of PN patients, contributing to the prevention of 
further neurological damage24.
In conclusion, our data suggest that increased attention 
should be paid to men by the leprosy control program because 
men present higher frequencies of MB forms and severe 
outcomes, including leprosy reactions and grade 2 physical 
impairment at diagnosis. Additionally, it is essential to develop 
strategies that emphasize the importance of performing the 
neurological examination and the adequate treatment of leprosy 
reactions to prevent physical impairment after treatment. 
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